StemCells Inc announced that interim six-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines. The third patient remains stable.
The data was presented by Armin Curt, M.D., principal investigator for the clinical trial, at the 51st Annual Scientific Meeting of the International Spinal Cord Society in London, England. The trial represents the first
Image via Wikipedia
It works in racehorses. Who knows if it’s possible in humans. A technique using stem cells to repair damage to the Achilles tendon is about to be tested in Great Britain.
British biotech company MedCell Bioscience has announced that it will begin human testing in the next six months and expects to perform a broad study in various European hospitals in 2011.
Patients will receive injections containing millions of their own stem cells extracted and multiplied in the lab to regenerate damaged tissue. Over 1,500 racehorses have been treated with the same procedure and the results
Another Heart Failure Patient Saved By Stem Cell Research
Barbro Lowed, a retired air hostess from London, England says that stem cell research using Adult Stem Cells removed from her bone marrow has given her her life back. Barbro had previously been suffering from congestive heart failure before the stem cell treatment. The heart failure was […]